The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

July 5, 2025

Primary Completion Date

December 17, 2025

Study Completion Date

December 17, 2026

Conditions

Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Interventions

PROCEDURE

Surgery with and without the aid of Indocyanine Green (ICG)

Enrolled patients will receive surgery and be follow up for 2 years

Trial Locations (1)

RECRUITING

The first affiliated hospital of SYSU, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT07064681 - The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | Biotech Hunter | Biotech Hunter